Pharmaco-EEG: a translational approach for profiling CNS candidates across diverse mechanisms of action at the preclinical stage
Why pharmaco-EEG matters in CNS drug development
CNS programs fail more than almost any other therapeutic area. Roughly 90% of drug candidates entering clinical trials never reach approval.
Four persistent gaps:
- Behavioral models that don’t reliably predict clinical outcome
- No translatable readout linking plasma exposure to central drug effect
- Little basis for benchmarking novel compounds against standards of care
- Fragmented, lab-specific measurement protocols
This is where Pharmaco-EEG comes in. Behavioral models tell you what an animal does. Pharmaco-EEG tells you what the drug does to the brain.
What pharmaco-EEG reveals about CNS drug candidates
Quantitative EEG (qEEG) opens a direct window onto brain activity, showing how a compound acts on cortical networks and whether it acts at all.
By running pharmaco-EEG studies at the preclinical stage, CNS drug developers can:
- Detect the EEG signature of a novel compound
- Benchmark it against clinically validated therapeutics
- Characterize PK/PD relationships
- Confirm central pharmacodynamic activity
- Establish dose-response effects
- Build a translational biomarker strategy that carries into the clinic
Pharmaco-EEG plays a pivotal role here. It turns central drug activity into objective, quantifiable biomarkers, giving teams evidence to benchmark a candidate against established compounds and make a data-driven go/no-go call before committing to the clinic.
Focus on antipsychotic drug
Schizophrenia affects approximately 24 million people worldwide. Current antipsychotics reduce positive symptoms such as hallucinations and delusions, but have limited impact on negative symptoms and cognitive impairment, the main determinants of long-term functional outcome.
The approval of Cobenfy (xanomeline-trospium chloride) in September 2024 broke a fifty-year pattern: the first antipsychotic to act on cholinergic rather than dopamine receptors. Results since have been mixed, with the adjunctive Phase 3 trial missing its primary endpoint in 2025.
This is precisely the situation where pharmaco-EEG earns its place. When a candidate acts outside the dopamine pathway, D2-based reference profiles no longer tell you what you need to know. An EEG signature does!
Focus on psychedelics:
Psychedelics are among the most active areas in psychiatric drug development. Classical compounds such as psilocybin, LSD, and DMT act through 5-HT2A receptors, while related entactogens such as MDMA work through a different pharmacology entirely.
A new generation of neuroplastogens aims to separate therapeutic benefit from hallucinogenic effect. Both hallucinogenic and non-hallucinogenic candidates are advancing, and whether the two can be uncoupled remains an open question.
The field is drawing serious capital. In July 2026, Eli Lilly announced an agreement to acquire AtaiBeckley for approximately $2.8 billion upfront, built around BPL-003, an intranasal 5-MeO-DMT for treatment-resistant depression.
Here, pharmaco-EEG is not just useful; it is close to essential. Psychedelics produce distinctive cortical signatures, including reduced alpha power and increased signal diversity. If the goal is a compound that retains the therapeutic effect without the subjective one, you need an objective measure of what the brain is actually doing. Behavioral readouts cannot answer that question. EEG can.